Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms

By Bhagwat Neha  

International Journal of Hematology, Vol. 97, Iss. 6, 2013-06 ,pp. : 695-702

Springer Publishing Company

Access to resources Recommend Favorite

Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms

By  

Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current Drug Targets - Cardiovascular & Hematological Disorders), Vol. 17, Iss. 3, 2018-02 ,pp. : 161-166

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Characterization of Neoplasms by Gene Expression Profiling and Genetic Aberrations, Abstract 154–158, Symposium

By Downing J R   Hiddemann W   Stoudt L M   Dalla-Favera R   Merz H  

Pathology Research and Practice, Vol. 199, Iss. 4, 2003-06 ,pp. : 219-219

Urban & Fischer

Access to resources Recommend Favorite

Molecular characterization of chronic myeloproliferative neoplasias in México

By Ruiz-Argüelles Guillermo J.   Garcés-Eisele Javier   Ortiz-López Rocio   Rivas-Llamas Ramón   Gómez-Almaguer David   Ruiz-Delgado Guillermo J.  

Hematology, Vol. 14, Iss. 5, 2009-10 ,pp. : 261-265

Maney Publishing

Access to resources Recommend Favorite

Molecular Markers in Myeloproliferative Disorders: From Classification to Prognosis?

By Pahl Heike L.  

Hematology, Vol. 8, Iss. 4, 2003-08 ,pp. : 199-209

Maney Publishing

Access to resources Recommend Favorite